Duova Rotacaps (Tiotropium Bromide and Formoterol Fumarate Dihydrate) used

Duova Rotacaps (Tiotropium Bromide and Formoterol Fumarate Dihydrate) contain a combination treatment used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), which is a progressive obstructive airways disease that usually gets worse with time. COPD has symptoms similar to asthma caused by bronchospasm, including tightness of the chest, wheezing and shortness of breath, as well as chronic cough with sputum production because the lung tissues have become damaged. Duova Rotacaps provides improved action to open airways and improve breathing, which helps relieve symptoms, where a single medication has not been sufficiently effective.

Duova Rotacaps (Tiotropium Bromide and Formoterol Fumarate Dihydrate) work

Duova Rotacaps (Tiotropium Bromide and Formoterol Fumarate Dihydrate) contains two bronchodlators that are used for long-term treatment chronic obstructive pulmonary disease (COPD). Formoterol in Duova Rotacaps is a potent, selective, long-acting beta-agonist that acts locally in the lungs and works as a bronchodilator by relaxing the smooth muscle in the airway walls to widen the airways. Tiotropium in Duova Rotacaps is a long-acting anticholinergic that acts on specific receptors (muscarinic receptors) in the bronchioles of the lung and inhibits the interaction of acetylcholine (a neurotransmitter or chemical messenger of the nervous system) with muscarinic receptors, which prevents spasm of the airway wall caused by acetylcholine. The synergistic action (interacting to enhance the action of each other) of the two drugs working together by different mechanisms, reduces bronchospasm (contraction of the airways) to a greater extent than would be provided by each drug alone and increases air flow into the lungs, relieving symptoms of COPD such as chronic cough with sputum production, tightness of the chest, wheezing and shortness of breath.